Epic Sciences to present CTC data on predictive tests at the Canaccord Genuity Forum.
Epic Sciences, Inc. ("Epic"), a private biotech company that designs and develops predictive tests of therapy response in cancer, announced today that Murali K. Prahalad, Ph.D., chief executive officer, will present at the Canaccord Genuity Medical Technology & Diagnostics Forum on Thursday, November 17, 2016 at 10:20 a.m. EST. The conference will be held at the Westin Grand Central in New York.
Epic recently announced its participation in the Cancer Moonshot Blood Profiling Atlas Pilot. It was the only CTC company invited to do so.
About Epic Sciences
At Epic Sciences, we develop clinically proven predictive tests to detect and monitor cancer at the individual cell level. With a proprietary rare-cell detection engine, we provide insights to clinical, biotech, pharmaceutical and academic teams on how cancer emerges, mutates and remits so they can make pivotal decisions at every point in patient treatment with greater certainty. Recognizing the unique nature of each person’s cancer, we offer truly personalized diagnostic tests, while being non-invasive for the patient.
We have developed the first clinically proven predictive test for metastatic castration-resistant prostrate cancer (mCRPC), the Epic AR-V7 test. Using the same rare-cell detection platform and Epic’s biobank of over 30,000 blood samples, each profiled with predictive biomarkers, we partner with leading pharmaceutical and biotechnology companies, major cancer centers, the National Cancer Institute (NCI), and the National Institutes of Health (NIH) to pursue additional predictive tests for breast, ovarian, colon and other cancers and diseases. Our mission is to revolutionize cancer care and therapies to make them as precise, safe and life-sustaining as humanly possible.
For more information, visit epicsciences.com.
Epic Sciences Media Contact: Jessica Yingling, Ph.D., Little Dog Communications Inc., email@example.com,+1.858.344.8091